The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer

Neoplasia (United States)

Volumn 15, Issue 2, 2013, Pages 133-142

  Bruno, Antonino ^a   Focaccetti, Chiara ^b   Pagani, Arianna ^c   Imperatori, Andrea S ^c   Spagnoletti, Marco ^c   Rotolo, Nicola ^c   Cantelmo, Anna Rita ^a   Franzi, Francesca ^c   Capella, Carlo ^c   Ferlazzo, Guido ^d   Mortara, Lorenzo ^c   Albini, Adriana ^b   Noonan, Douglas M ^a,c  

^a IRCCS MULTIMEDICA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD31 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL ISOLATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MORPHOGENESIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

EID: 84873501144     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121758     Document Type: Article

References (51)

1. Schreiber RD, Old LJ, and Smyth MJ (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570.
2. de Visser KE, Eichten A, and Coussens LM (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37.
3. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, and Albini A (2008). Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27, 31-40.
4. Mantovani A and Sica A (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22, 231-237.
5. Qian BZ and Pollard JW (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51.
6. Spits H and Cupedo T (2012). Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30, 647-675.
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, and Ugolini S (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49.
8. Moretta A, Locatelli F, and Moretta L (2008). Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev 224, 58-69.
9. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, et al. (2006). Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12, 1065-1074.
10. Santoni A, Carlino C, Stabile H, and Gismondi A (2008). Mechanisms underlying recruitment and accumulation of decidual NK cells in uterus during pregnancy. Am J Reprod Immunol 59, 417-424.
11. Vacca P, Moretta L, Moretta A, and Mingari MC (2011). Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol 32, 517-523.
12. Ferlazzo G and Munz C (2009). Dendritic cell interactions with NK cells from different tissues. J Clin Immunol 29, 265-273.
13. Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L, Moretta A, and Ferlazzo G (2012). Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One 7, e39170.
14. Culley FJ (2009). Natural killer cells in infection and inflammation of the lung. Immunology 128, 151-163.
15. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, and Walzer T (2007). The trafficking of natural killer cells. Immunol Rev 220, 169-182.
16. Ge N, Nishioka Y, Nakamura Y, Okano Y, Yoneda K, Ogawa H, Sugita A, Yanagawa H, and Sone S (2004). Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int Arch Allergy Immunol 135, 235-242.
17. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, and Ferlazzo G (2008). Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 112, 863-875.
18. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF, et al. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71, 5412-5422.
19. Flavell RA, Sanjabi S, Wrzesinski SH, and Licona-Limon P (2010). The polarization of immune cells in the tumour environment by TGFβ Nat Rev Immunol 10, 554-567.
20. Ikushima H and Miyazono K (2010). TGFβ signalling: A complex web in cancer progression. Nat Rev Cancer 10, 415-424.
21. Lee JC, Lee KM, Kim DW, and Heo DS (2004). Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172, 7335-7340.
22. Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H, Fiegl M, and Tzankov A (2011). High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 43, 339-349.
23. Allan DS, Rybalov B, Awong G, Zuniga-Pflucker JC, Kopcow HD, Carlyle JR, and Strominger JL (2010). TGF-β affects development and differentiation of human natural killer cell subsets. Eur J Immunol 40, 2289-2295.
24. - NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 104, 3378-3383.
25. Albini A and Noonan DM (2010). The 'chemoinvasion' assay, 25 years and still going strong: the use of reconstituted basement membranes to study cell invasion and angiogenesis. Curr Opin Cell Biol 22, 677-689.
26. Albini A and Benelli R (2007). The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2, 504-511.
27. Cantelmo AR, Cammarota R, Noonan DM, Focaccetti C, Comoglio PM, Prat M, and Albini A (2010). Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene 29, 5286-5298.
28. Cooper MA, Fehniger TA, and Caligiuri MA (2001). The biology of human natural killer-cell subsets. Trends Immunol 22, 633-640.
29. Indraccolo S, Pfeffer U, Minuzzo S, Esposito G, Roni V, Mandruzzato S, Ferrari N, Anfosso L, Dell'Eva R, Noonan DM, et al. (2007). Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 178, 1122-1135.
30. + NK-cell subset. Blood 116, 3865-3874.
31. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, and Callol L (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35, 23-28.
32. Murphy SP, Tayade C, Ashkar AA, Hatta K, Zhang J, and Croy BA (2009). Interferon gamma in successful pregnancies. Biol Reprod 80, 848-859.
33. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol 27, 1227-1234.
34. Kossenkov AV, Vachani A, Chang C, Nichols C, Billouin S, Horng W, Rom WN, Albelda SM, Showe MK, and Showe LC (2011). Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res 17, 5867-5877.
35. Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, Chang C, Kucharczuk J, Tran B, Wakeam E, et al. (2009). Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 69, 9202-9210.
36. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, and Bremnes RM (2010). Combination of low vascular endothelial growth factor A (VEGF-A)/ VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 116, 4318-4325.
37. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, and Ichinose Y (2006). Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53, 91-96.
38. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, and Yasumoto K (1998). Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115, 1007-1014.
39. Regina S, Rollin J, Blechet C, Iochmann S, Reverdiau P, and Gruel Y (2008). Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 3, 689-697.
40. Holtan SG, Creedon DJ, Thompson MA, Nevala WK, and Markovic SN (2011). Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol 2011, 316314.
41. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Izawa S, and Fujii H (2010). NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus 23, 675-681.
42. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, and Cook GP (2011). Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 6, e22842.
43. Carosella ED (2011). The tolerogenic molecule HLA-G. Immunol Lett 138, 22-24.
44. Yan WH (2011). Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett 311, 123-130.
45. Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, and Rebmann V (2010). Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 71, 489-495.
46. Yie SM, Yang H, Ye SR, Li K, Dong DD, and Lin XM (2007). Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 58, 267-274.
47. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, and Kaneko M (1994). Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 24, 199-204.
48. Aoki T, Nakata H, Watanabe H, Nakamura K, Kasai T, Hashimoto H, Yasumoto K, and Kido M (2000). Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 174, 763-768.
49. Hasegawa M, Sone S, Takashima S, Li F, Yang ZG, Maruyama Y, and Watanabe T (2000). Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 73, 1252-1259.
50. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallieres E, and Goldstraw P (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2, 593-602.
51. Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, Nishimura M, and Nagai K (2012). Differences between squamous cell carcinoma and adeno-carcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal? Jpn J Clin Oncol 42, 189-195.